ライフサイエンスコーパス: JRA

1 JRA affected sibpair families had an increased prevalenc

2 JRA and JSpA synovia are characterized by the presence o

3 JRA cases reported significantly lower rates of employme

4 JRA patients followed at a tertiary pediatric rheumatolo

5 JRA patients were dichotomized into those with "normal"

6 JRA synovium is characterized by high angiogenic activit

7 ciarticular- or systemic-onset disease), 100 JRA ASPs, and 688 healthy children were tested for anti-

8 DNA from 119 JRA patients (72 pauciarticular, 47 polyarticular) and 1

9 RA patients with polyarticular disease and 2 JRA patients with pauciarticular disease (1 with early o

10 Families of 23 JRA affected sibpairs were interviewed subsequently.

11 In a cross-sectional study, 48 JRA patients and 25 healthy control subjects ages 4.6-11

12 cell disorder which can be associated with a JRA-like polyarthritis.

13 Active JRA is associated with lower levels of platelet activati

14 Ten patients with active JRA were treated with CCII for 12 weeks.

15 oduction is impaired in children with active JRA.

16 inically in prepubertal children with active JRA.

17 All JRA patients had decreased tibia trabecular bone density

18 and thrombin receptors, were present in all JRA tissue specimens studied.

19 es in disease duration, race, JRA onset, and JRA course between groups, children with Medicaid status

20 reas of bone erosion in patients with RA and JRA.

21 g focal bone erosion in patients with RA and JRA.

22 s in both normal muscle biopsy specimens and JRA synovial tissue specimens.

23 ial impact of juvenile rheumatoid arthritis (JRA) among a population-based cohort of adults who had t

24 itis (RA) and juvenile rheumatoid arthritis (JRA) and can result in significant morbidity.

25 polyarticular juvenile rheumatoid arthritis (JRA) and pauciarticular/juvenile spondylarthropathy (SpA

26 mechanisms of juvenile rheumatoid arthritis (JRA) have been debated.

27 ystemic-onset juvenile rheumatoid arthritis (JRA) have persistently active disease with joint destruc

28 prevalence of juvenile rheumatoid arthritis (JRA) in Rochester, Minnesota, over 33 years.

29 polyarticular juvenile rheumatoid arthritis (JRA) in the general population.

30 Juvenile rheumatoid arthritis (JRA) is a chronic systemic disease of childhood that aff

31 hallmarks of juvenile rheumatoid arthritis (JRA) is a tumor-like expansion of inflamed synovial tiss

32 flammation in juvenile rheumatoid arthritis (JRA) is sometimes associated with an autoimmune response

33 samples from juvenile rheumatoid arthritis (JRA) patients using three-color flow cytometric analysis

34 vial fluid of juvenile rheumatoid arthritis (JRA) patients.

35 icular-course juvenile rheumatoid arthritis (JRA) provided rapid clinical improvement that was sustai

36 Juvenile rheumatoid arthritis (JRA) remains a challenge for clinicians.

37 Juvenile rheumatoid arthritis (JRA) represents a heterogeneous group of disorders with

38 ic studies of juvenile rheumatoid arthritis (JRA) synovium, the available data on angiogenesis in JRA

39 treatment of juvenile rheumatoid arthritis (JRA) that have appeared during the past year.

40 patients with juvenile rheumatoid arthritis (JRA) were used for additional comparison.

41 children with juvenile rheumatoid arthritis (JRA), or 23 healthy children, from the same geographic a

42 patients with juvenile rheumatoid arthritis (JRA), particularly in those with polyarticular, rheumato

43 children with juvenile rheumatoid arthritis (JRA).

44 with systemic juvenile rheumatoid arthritis (JRA).

45 e subtypes of juvenile rheumatoid arthritis (JRA).

46 destructive, juvenile rheumatoid arthritis (JRA).

47 The difference in age at JRA onset within sibpairs (sibling 1 versus sibling 2) w

48 ogistic regression, a model including age at JRA onset, Juvenile Arthritis Functional Assessment Repo

49 xception is the number of affected joints at JRA onset among patients with polyarticular-onset diseas

50 When stratified by JRA onset type, excess allele sharing was demonstrated a

51 For comparison, JRA patients were divided into "low" TB BMD (Z score < o

52 rofile in children with polyarticular-course JRA and provides significant improvement in disease mani

53 Patients with active polyarticular-course JRA who participated in an efficacy study continued etan

54 Thirty-six females with definite JRA who had never received corticosteroids and 51 health

55 n selected children with severe, destructive JRA.

56 al developmental aberrations in experimental JRA-like disease of the TMJ that are similar to those ob

57 ere measured by ELISA in JRA synovial fluid, JRA plasma, adult rheumatoid arthritis synovial fluid, a

58 ibpairs were concordant for sex, and 76% for JRA onset type.

59 Total-body BMC Z-scores were calculated for JRA patients using data from controls.

60 lazine are relatively safe and effective for JRA.

61 These findings for JRA are consistent with findings for other autoimmune di

62 Long-term use of MTX for JRA does not appear to be associated with the developmen

63 re registered with the Research Registry for JRA ASPs (sponsored by the National Institute of Arthrit

64 A genome-wide scan for JRA in 121 affected sibling pair families confirms that

65 nti-DEK autoantibodies are less specific for JRA than previously believed.

66 CCII may be a safe and effective therapy for JRA, and its use in this disease warrants further invest

67 vity was found at the following frequencies: JRA 39.4% (n = 71), systemic lupus erythematosus (SLE) 2

68 ssion of the key angiogenic factors in fresh JRA synovium and in JRA synovial tissue fragments that h

69 n of the key angiogenic factors in the fresh JRA tissues correlated with the exuberant revascularizat

70 Adults who have had JRA during childhood experience long-term physical and p

71 m were considered healthy and 18 of whom had JRA.

72 SCID mouse-human JRA synovium chimeras may provide a good approach to stu

73 In JRA patients, IGF-1, IGFBP-3, and osteocalcin levels wer

74 f autoimmunity to CII can be accomplished in JRA by oral administration of CII, an open-label study o

75 usion protein to block TNF-alpha activity in JRA has further contributed to this finding.

76 iogenic factors in fresh JRA synovium and in JRA synovial tissue fragments that had been minced and t

77 ovium, the available data on angiogenesis in JRA are very limited.

78 dy the in vivo regulation of angiogenesis in JRA.

79 Anti-CCP antibodies in JRA are associated with polyarticular onset, a polyartic

80 overall prevalence of anti-CCP antibodies in JRA is low, but a substantial proportion of RF-positive

81 mulations of both CCR4+ and CCR5+ T cells in JRA synovial fluids and a correlation for increased numb

82 he possible beneficial effect of oral CII in JRA merits further investigation.

83 tivation-regulated chemokine was detected in JRA synovial fluid and plasma samples, but not in adult

84 isms for altered craniofacial development in JRA of the TMJ, we characterized the gross morphologic a

85 ted quality of life and higher disability in JRA.

86 ligands for CCR4, were measured by ELISA in JRA synovial fluid, JRA plasma, adult rheumatoid arthrit

87 expression of the key angiogenic factors in JRA synovium, and to evaluate a SCID mouse model of JRA

88 The levels of expression of these factors in JRA tissues were significantly higher than those in tiss

89 lation of the expression of these factors in JRA.

90 ed decreases in markers of bone formation in JRA patients.

91 sed the use of intravenous gamma globulin in JRA.

92 sis and appropriate monitoring guidelines in JRA.

93 e diseases, including immunodeficiencies, in JRA patients.

94 incidence of celiac disease was increased in JRA patients.

95 ine levels and their role in inflammation in JRA.

96 Total-body BMC was 4.5% lower in JRA patients than in controls (mean +/- SD 2,050 +/- 379

97 ion between decreased bone mineralization in JRA and low bone formation that is related to disease se

98 age microstructure differences that occur in JRA.

99 Disease-related parameters in JRA appear to exert a negative effect on bone mineraliza

100 ermine the different roles cytokines play in JRA subtypes and would contribute to the development of

101 ucers of the ongoing inflammatory process in JRA.

102 nercept confirmed its efficacy and safety in JRA.

103 BMD was decreased in all sites in JRA patients.

104 ation of newly formed vascular structures in JRA synovium.

105 porine for macrophage activation syndrome in JRA.

106 w will focus on some recent cellular work in JRA and also further evaluation of cytokine levels and t

107 SLE than in other patient subsets, including JRA.

108 ellitus, inflammatory bowel disease, iritis, JRA, multiple sclerosis, psoriasis, RA, systemic lupus e

109 ously shown that revascularization of minced JRA synovial tissues engrafted into SCID mice correlated

110 TNF beta expression was demonstrated in most JRA and JSpA tissues, although samples from patients wit

111 Seven rheumatoid factor-negative JRA patients with polyarticular disease and 2 JRA patien

112 ntial role of interleukin-6 in the anemia of JRA patients.

113 t database was used to identify all cases of JRA (based on the American College of Rheumatology [form

114 t database was used to identify all cases of JRA diagnosed among Rochester, Minnesota residents under

115 records screened, we identified 65 cases of JRA diagnosed between 1960 and 1993 (48 females, 17 male

116 In addition, all cases of JRA from our previously identified cohort from 1960-1979

117 Comparison of JRA patients with "normal" versus those with "low" total

118 er residents with any potential diagnoses of JRA from 1978 to 1993 (based on the American College of

119 to the cases as of the date of diagnosis of JRA.

120 all subtypes indicated a localized effect of JRA on bone.

121 ion-based cohort of adults with a history of JRA in comparison with the rate in the general populatio

122 ontrol cohort of subjects with no history of JRA.

123 n this cohort of 57 adults with a history of JRA.

124 mmune responses in the immunopathogenesis of JRA, and their effect on cytokine release.

125 dies may underestimate the true incidence of JRA if visits of physicians are the only basis for the s

126 Linkage of JRA to the HLA region was confirmed (logarithm of odds [

127 Additional evidence supporting linkage of JRA was observed at 1p36 (D1S214; LOD 1.65), 19p13 (D19S

128 demographics and clinical manifestations of JRA.

129 ovium, and to evaluate a SCID mouse model of JRA as an approach to study in vivo regulation of the ex

130 of these complexes in the pathophysiology of JRA remain unclear.

131 ined for up to 8 years in this population of JRA patients.

132 among first- and second-degree relatives of JRA patients.

133 ated with the exuberant revascularization of JRA minced tissue fragments implanted into SCID mice.

134 t IgM affinity-purified ICs from the sera of JRA patients contain IgM, C1q, IgG, and C3 to a variable

135 e treated with ICs isolated from the sera of JRA patients.

136 a in the synovium in particular subgroups of JRA patients and in JSpA patients may be a distinguishin

137 fluence susceptibility to JRA or subtypes of JRA.

138 Improvements in the signs and symptoms of JRA were also maintained for up to 8 years.

139 s are safe and effective in the treatment of JRA.

140 cted degree of concordance for onset type of JRA exists between sibpairs, indicating that genetic inf

141 s and between patients with the same type of JRA suggests the recognition of a common or limited grou

142 rch registry was established with a focus on JRA ASPs to facilitate accrual of patients for genetic,

143 n families that had a child with pauci-onset JRA and at least 1 parent who was heterozygous for the a

144 r histocompatibility complex and pauci-onset JRA.

145 ercent of the cases had pauciarticular-onset JRA, 16% had polyarticular-onset JRA, and 11% had system

146 mRNA and IL-10 mRNA in pauciarticular-onset JRA.

147 SPs were concordant for pauciarticular-onset JRA; 19% were concordant for a polyarticular disease ons

148 ent of the patients with polyarticular-onset JRA and 2% of the other JRA patients exhibited anti-CCP

149 F-positive patients with polyarticular-onset JRA had anti-CCP antibodies.

150 F-positive patients with polyarticular-onset JRA have these antibodies.

151 4-positive patients with polyarticular-onset JRA were more likely to have anti-CCP antibodies than we

152 cular-onset JRA, 16% had polyarticular-onset JRA, and 11% had systemic-onset JRA.

153 pauciarticular-onset and polyarticular-onset JRA.

154 4-positive patients with polyarticular-onset JRA.

155 rations seen in children with systemic-onset JRA correlated closely with elevations in the ESR and pl

156 pro-inflammatory response in systemic-onset JRA manifested by increased secretion of interleukin-6,

157 amples from children with the systemic-onset JRA subtype had elevated concentrations of FSTL-1.

158 group of children with severe systemic-onset JRA was treated in an attempt to control active synoviti

159 oarticular, polyarticular, or systemic-onset JRA were assayed for FSTL-1 using a custom enzyme-linked

160 Four patients with systemic-onset JRA were continued on a daily regimen of nonsteroidal an

161 children with JRA, especially systemic-onset JRA, whose disease has been refractory to conventional t

162 marker of disease activity in systemic-onset JRA.

163 icular-onset JRA, and 11% had systemic-onset JRA.

164 ovial fluid or tissue of patients with RA or JRA.

165 polyarticular-onset JRA and 2% of the other JRA patients exhibited anti-CCP antibodies, compared wit

166 Children with pauci JRA who had asymmetric lower-extremity arthritis diagnos

167 d with less LLD in young children with pauci JRA.

168 usly reported linkage between pauciarticular JRA and the HLA-DR region that was identified using a di

169 6.6 years, respectively, for pauciarticular JRA and St0.5 values of 10.2 and 10.7 years, respectivel

170 y role in the pathogenesis of pauciarticular JRA and may protect, along with IL-10, against the devel

171 with early susceptibility to pauciarticular JRA, including HLA-A2, DR8, DR5, and DPB1*0201.

172 in samples from patients with pauciarticular JRA and juvenile SpA while single large Vbeta8-specific

173 gh samples from patients with pauciarticular JRA had somewhat lesser amounts of these cytokines.

174 s evidence for linkage between polyarticular JRA and the HLA-DR region.

175 10.7 years, respectively, for polyarticular JRA.

176 lized skeleton was observed in polyarticular JRA.

177 anding, methotrexate-resistant polyarticular JRA demonstrated sustained clinical improvement with >2

178 with HLA-DR4 in children with polyarticular JRA, whether anti-CCP antibodies are associated with cli

179 lyarticular, rheumatoid factor (RF)-positive JRA.

180 at in a mildly to moderately ill prepubertal JRA population that had never been exposed to corticoste

181 n for differences in disease duration, race, JRA onset, and JRA course between groups, children with

182 Systemic JRA was associated with a shorter, less mineralized skel

183 Children with systemic JRA had lower femoral neck densities.

184 uring fever spikes in children with systemic JRA.

185 h the greatest use in children with systemic JRA.

186 We conclude that JRA and its clinical manifestations do not differ substa

187 uency of deaths in this cohort suggests that JRA patients are at substantial risk for mortality, and

188 The JRA 30% definition of improvement (DOI) was defined as i

189 The JRA subjects with low TB BMD were significantly younger,

190 247 affected children in North America (the JRA Affected Sibpair [ASP] Registry).

191 SD TB BMD scores did not differ between the JRA subjects (0.75 +/- 0.06 gm/cm2) and controls (0.73 +

192 asures were in the normal range for both the JRA and the case-control groups.

193 The mean Z score for the JRA patients with low TB BMD was -1.43, and for those wi

194 s found significantly more frequently in the JRA affected sibpair families, but not in the simplex fa

195 e findings suggest that CCR4+ T cells in the JRA joint may function early in disease in an anti-infla

196 0.0006, 0.003, and 0.019) of disease in the JRA, pauciarticular, and polyarticular patient groups, r

197 Of these 43 patients, 81% met the JRA 30% DOI, 79% met the JRA 50% DOI, and 67% met the JR

198 tients, 81% met the JRA 30% DOI, 79% met the JRA 50% DOI, and 67% met the JRA 70% DOI.

199 OI, 79% met the JRA 50% DOI, and 67% met the JRA 70% DOI.

200 Details of the JRA Affected Sibpair Registry operations have been descr

201 However, 29.2% of the JRA patients had low TB BMD, whereas only 16% would be e

202 as able to accurately segregate 79.6% of the JRA subjects into either the low or normal TB BMD groups

203 e same marker that supported linkage to the "JRA" phenotype.

204 asymmetric joint involvement, in contrast to JRA patients.

205 nome scan was performed to detect linkage to JRA in 121 families containing 247 affected children in

206 n the HLA region influence susceptibility to JRA and identifies other chromosomal regions that possib

207 e NRAMP1 allele conferring susceptibility to JRA drives high levels of NRAMP1 expression, while the a

208 ns that possibly influence susceptibility to JRA or subtypes of JRA.

209 the HLA region, influence susceptibility to JRA.

210 mild-to-moderate, non-corticosteroid-treated JRA had low bone mass.

211 Another report described two JRA patients who developed nodules while receiving metho

212 e overall survival functions for the various JRA subtype and sex categories.

213 cess sharing of 2 DR alleles among ASPs with JRA.

214 d whether affected sibling pairs (ASPs) with JRA are concordant for this antibody.

215 and adolescents (141 girls and 57 boys) with JRA, ages 6 to 18 years, with a mean +/- SD age of 11.7

216 ng the advent of hip disease in a child with JRA warns of future disability [1, 2].

217 ore internalizing symptoms in the child with JRA, but child self reports and father reports showed no

218 to NSAIDs was monitored in 48 children with JRA (mean age 8.6 years) over 28 consecutive days using

219 Using a case-control design, children with JRA (n = 74), ages 8-14, were compared with case-control

220 ual x-ray absorptiometry in 41 children with JRA and 62 healthy children.

221 Eighteen prepubertal children with JRA and growth retardation received recombinant human gr

222 e drugs are resulting in fewer children with JRA developing into severe hip disease requiring hip sur

223 Forty (14%) of the 295 children with JRA had Medicaid status.

224 Children with JRA had more relatives with rheumatoid arthritis (P = 0.

225 Children with JRA have decreased skeletal size, muscle mass, trabecula

226 ere significantly decreased in children with JRA receiving calcium supplementation.

227 rage T2 relaxation time in the children with JRA suggests that T2 relaxation time maps may reflect ca

228 Children with JRA were remarkably similar to case-control children on

229 ve to case-control classmates, children with JRA were similar on all measures of social functioning a

230 plantation, may offer hope for children with JRA, especially systemic-onset JRA, whose disease has be

231 psychological hardiness among children with JRA.

232 TBBMD compared with placebo in children with JRA.

233 sease develops in 30 to 50% of children with JRA.

234 in and vitamin D in their diet compared with JRA patients with normal TB BMD (all P < 0.05).

235 Children newly diagnosed with JRA are more likely to adhere to an NSAID regimen if the

236 were significantly higher in the girls with JRA than in the group of healthy girls (P < 0.05).

237 Individuals with JRA of the TMJ frequently show aberrations in mandibulof

238 Other regions supporting linkage with JRA disease subtype included 20q13, 4q24, 12q24, and Xp1

239 es obtained from 230 HLA-typed patients with JRA (77 with polyarticular-onset disease and 153 with pa

240 We typed 680 patients with JRA and 254 ethnically matched unrelated controls for HL

241 uid, and peripheral blood from patients with JRA and juvenile SpA was cloned and sequenced.

242 Physicians likely to care for patients with JRA were made aware of the registry and its goals by a v

243 n a cross-section cohort of 14 patients with JRA who had received a total cumulative dose of MTX that

244 Patients with JRA who previously participated in a randomized controll

245 t synovial tissue samples from patients with JRA, 6 from patients with JSpA, and 6 from patients with

246 otection (window-of-effect) in patients with JRA.

247 ars of etanercept treatment in patients with JRA.

248 tudy of CII was performed in 9 patients with JRA.

249 Eighty pairs of siblings with JRA who were registered with the Research Registry for J

250 in healthy controls (90%) than in those with JRA (64%), suggesting a common environmental exposure.

251 Forty-eight children ages 4-18 years with JRA (17 pauciarticular, 23 polyarticular, 8 systemic) we